December 6, 2024

MEDIPAL HOLDINGS CORPORATION
Representative: Shuichi Watanabe, Representative Director, President and CEO
Code number: 7459 (Prime Market, Tokyo Stock Exchange)
Contact: Yuji Sakon,
Managing Director, General Manager of Administration Division
Tel: +81-3-3517-5171

Notice of Joint Investment

MEDIPAL HOLDINGS CORPORATION (the "Company") hereby provides notice of the decision to invest directly or indirectly (the "Investment") in the acquisition of all shares of Teva Takeda Pharma Ltd. (including Teva Takeda Yakuhin Ltd. (Head office: Nakamura-ku, Nagoya-shi and Shibuya-ku, Tokyo; President & CEO: Yoshihiro Toyohara; "Teva Takeda"), a wholly owned subsidiary of Teva Takeda Pharma Ltd.) by the investment vehicle ("Buyer") managed and operated by J-Will Partners Co., Ltd. (Head office: Chiyoda-ku, Tokyo; President: Yuichiro Eda; "JWP"). The Company plans to take a 20% investment stake in the Buyer.

1. Purpose of investment

The Company aims to build sustainable logistics, a growth strategy in the 2027 MEDIPAL Medium-Term Vision, Change the *Oroshi* Forever—Constant Innovation, based on our management philosophy of "Contributing to people's health and the advancement of society through creation of value in distribution."

One initiative aimed at implementing that growth strategy has been investment in the generic drug manufacturers Nichi-Iko Pharmaceutical Co., Ltd. (Head office: Toyama-shi, Toyama; President: Shingo Iwamoto) and KYOWA Pharmaceutical Industry Co., Ltd. (Headquarters: Kita-ku, Osaka-shi; President: Minoru Inemura) jointly with the fund managed and operated by JWP. We have been working to build a production distribution model to deliver generic drugs[1] to patients consistently and efficiently through continual improvement of quality assurance systems, planned production, and other initiatives at the investees.

Amid these efforts, the Company has explored the Investment in Teva Takeda, which mainly develops, manufactures, and sells long-listed products[2] and generic drugs.

In the generic drug industry, multiple generic drug manufacturers produce and sell the same product. A small lot, high-mix production structure also poses challenges and there are increasing opportunities to push for industry restructuring. The Investment will further advance existing initiatives with the investees and we aim to develop a structure that is better able to safely deliver quality generic drugs to the patients who need them.

2. Future outlook

This joint investment will have no effect on business performance in the fiscal year ending March 31, 2025.

About Teva Takeda Pharma Ltd.

Teva Takeda Pharma Ltd. is a joint venture established on April 1, 2016 by Takeda Pharmaceutical Company Limited (“Takeda Pharmaceutical”) and Teva Pharmaceutical Industries Ltd. It handles generic drugs.

About Teva Takeda Yakuhin Ltd.

Teva Takeda Yakuhin Ltd. handles long-listed drugs acquired from Takeda Pharmaceutical.

1 Generics (generic drugs):

Prescription drugs for which patent period on the new drug has expired and for which the reexamination period has ended, and are approved by the Ministry of Health, Labour and Welfare for manufacture and sale.

2 Long-listed products:

Prescription pharmaceuticals for which the patent period has expired due to time elapsed after development and sale as a new drug and for which the reexamination period, during which the pharmaceutical manufacturer gathers data on actual use in hospitals and clinics and reconfirms safety and efficacy, has ended. They refer to pharmaceuticals that can be used for insured treatment and are called long-listed products because they have been listed on the nationally determined price list for a long time.

The English version of this document is a translation of the Japanese original and is provided for information purposes only. While reasonable efforts have been made to provide an accurate translation, no liability is assumed by MEDIPAL HOLDINGS CORPORATION for any errors, omissions, or ambiguities in the translation. In the event of any inconsistency or conflict between the English version and the Japanese original, the Japanese original shall prevail.